Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03437564
Recruitment Status : Completed
First Posted : February 19, 2018
Results First Posted : June 26, 2019
Last Update Posted : June 27, 2019
Sponsor:
Information provided by (Responsible Party):
Takeda

Brief Summary:
The purpose of this study is to evaluate the bioequivalence of a single oral administration of a vortioxetine (Lu AA21004) 20 mg tablet in comparison with two of vortioxetine 10 mg tablets in Japanese healthy adult participants.

Condition or disease Intervention/treatment Phase
Healthy Adult Participants Drug: Vortioxetine Phase 1

Detailed Description:

The drug being tested in this study is called vortioxetine (Lu AA21004). Vortioxetine is being tested in Japanese healthy adult participants. This study will look at the bioequivalence of a single oral administration of a vortioxetine 20 mg tablet in comparison with two of vortioxetine 10 mg tablets, and also look at the safety of a single oral dose of vortioxetine 20 mg in Japanese healthy adult participants.

The study will enroll 28 (14 for each sequence) healthy participants. In case bioequivalence cannot be demonstrated with the number of participants initially planned, an add-on participant study may be conducted (as a maximum 28 participants additionally). Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups.

  • Treatment Group A: Vortioxetine 20 mg (one 20 mg tablet) in Period 1 + Vortioxetine 20 mg (two 10 mg tablets) in Period 2
  • Treatment Group B: Vortioxetine 20 mg (two 10 mg tablets) in Period 1 + Vortioxetine 20 mg (one 20 mg tablet) in Period 2

This single-center trial will be conducted in Japan. The overall time to participate in this study is approximately 25 days. Participants will make two visits to the clinic and be hospitalized for ten days in total.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Randomized, Open-Label, 2×2 Crossover Phase 1 Study to Evaluate the Bioequivalence of Single Oral Dose of Lu AA21004 20 mg Tablet and 2× Lu AA21004 10 mg Tablets in Healthy Adult Subjects
Actual Study Start Date : February 16, 2018
Actual Primary Completion Date : April 13, 2018
Actual Study Completion Date : April 13, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Vortioxetine one 20 mg tablet + two 10 mg tablets
Vortioxetine 20 mg (one 20 mg tablet) on Day 1 in Period 1 in a fasted state + vortioxetine 20 mg (two 10 mg tablets) on Day 1 in Period 2 in a fasted state.
Drug: Vortioxetine
Vortioxetine tablet
Other Name: Lu AA21004

Experimental: Vortioxetine two 10 mg tablets + one 20 mg tablet
Vortioxetine 20 mg (two 10 mg tablets) on Day 1 in Period 1 in a fasted state + vortioxetine 20 mg (one 20 mg tablet) on Day 1 in Period 2 in a fasted state.
Drug: Vortioxetine
Vortioxetine tablet
Other Name: Lu AA21004




Primary Outcome Measures :
  1. AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Time Point of Unchanged Lu AA21004 [ Time Frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose ]
  2. Cmax: Maximum Plasma Concentration (Observed Value) of Unchanged Lu AA21004 [ Time Frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose ]

Secondary Outcome Measures :
  1. AUC∞: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity of Unchanged Lu AA21004 [ Time Frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose ]
  2. Tmax: Time to Reach Cmax (Observed Value) of Unchanged Lu AA21004 [ Time Frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose ]
  3. MRT∞, ev: Mean Residence Time 0 to Infinity of Unchanged Lu AA21004 [ Time Frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose ]
  4. MRTlast, ev: Mean Residence Time From Time 0 to the Time of the Last Quantifiable Concentration of Unchanged Lu AA21004 [ Time Frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose ]
  5. λz: Apparent Elimination Rate Constant of Unchanged Lu AA21004 [ Time Frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose ]
  6. T1/2z: Apparent Elimination Half-Life of Unchanged Lu AA21004 [ Time Frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose ]
  7. Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE) [ Time Frame: Up to Day 25 ]
  8. Number of Participants With TEAE Related to Vital Sign [ Time Frame: Up to Day 25 ]
  9. Number of Participants With TEAE Related to Clinical Laboratory Tests (Alanine Aminotransferase Increased) [ Time Frame: Up to Day 25 ]
  10. Number of Participants With TEAE Related to 12-lead Electrocardiograms [ Time Frame: Up to Day 25 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Be a healthy Japanese adult volunteer.
  2. Understand the contents of the study and is capable of providing written consent to participate in the study.
  3. Be willing to comply with all study procedures and restrictions.
  4. Aged between ≥20 and ≤45 years at the time of screening.
  5. Have a BMI of ≥18.5 and ≤24.9 (kg/m^2) and a body weight of ≥50 kg at the time of screening.
  6. Be a extensive metabolizer (EM) based on CYP2D6 genotyping at the time of screening.
  7. A female participant of childbearing potential with a non-sterilized male partner must agree to routinely use appropriate contraception during the study from the time of signing informed consent until 4 weeks after last dosing of the study drug.

Exclusion Criteria:

  1. Has received any investigational drug within 90 days before screening for this study.
  2. Previously received Lu AA21004 before participation in this study.
  3. Is an employee of the sponsor or the study site, or immediate family member, or is in a dependent relationship with a study site employee who is involved in the conduct of this study (eg, spouse, parent, child, sibling) or who may be coerced to provide consent.
  4. Has uncontrolled, clinically relevant neurologic, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, or endocrine disease or other abnormality which may affect study participation or study results.
  5. Has a history of multiple episodes or severe allergies (eg, food, drug, latex allergy) or has had an anaphylactic reaction or significant intolerance to prescription drugs, over the counter (OTC) drugs, or foods.
  6. Has a positive pregnancy test at the time of screening or Day −1.
  7. Is a pregnant or lactating female.
  8. Has a positive urine drug screen test at the time of screening or Day −1.
  9. Has a history of drug abuse (defined as any illicit drug use) or has a history of alcohol dependence within 2 years before the start of screening or is unwilling to agree to abstain from alcohol and drugs throughout the study.
  10. Consumes 6 or more servings of caffeinated beverages (containing about 120 mg of caffeine per serving) such as of coffee, tea, cola, or energy drinks.
  11. Is a smoker who smoked cigarettes or used nicotine-containing products (such as nicotine patch) within 6 months before the Period 1 study drug administration.
  12. Used any of the excluded drugs, dietary products or foods during the specified time periods, or will need any of them during the study period.
  13. Has any current or recent gastrointestinal diseases that would be expected to influence the absorption of drugs (ie, a history of malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis, frequent [more than once per week] occurrence of heartburn), or any surgical intervention (Stomach, cholecystectomy etc.).
  14. Has a history of cancer.
  15. Has a positive test result for any of the following at the time of screening: hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody/antigen, serological test for syphilis.
  16. Has poor peripheral venous access.
  17. Has undergone whole blood collection of at least 200 mL within 4 weeks (28 days) or at least 400 mL within 12 weeks (84 days) prior to the start of Period 1 study drug administration.
  18. Has undergone whole blood collection of at least 800 mL in total within 52 weeks (364 days) prior to the start of Period 1 study drug administration.
  19. Has undergone blood component collection within 2 weeks (14 days) prior to the start of Period 1 study drug administration.
  20. Has any clinically relevant abnormality in vital signs or 12-lead electrocardiograms (ECG) at screening or on Day −1 of Period 1.
  21. Has abnormal laboratory test values at screening or on Day −1 of Period 1 indicating clinically relevant underlying disease, or showing alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >1.5×upper limit of normal (ULN).
  22. Is unlikely to comply with the protocol requirements or is unsuitable as a participant of this study for any other reason in the opinion of the investigator or sub-investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03437564


Locations
Layout table for location information
Japan
Nishi Kumamoto Hospital
Kumamoto, Japan
Sponsors and Collaborators
Takeda
Investigators
Layout table for investigator information
Study Director: Study Director Takeda
  Study Documents (Full-Text)

Documents provided by Takeda:
Study Protocol  [PDF] February 15, 2018
Statistical Analysis Plan  [PDF] June 14, 2018


Layout table for additonal information
Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT03437564     History of Changes
Other Study ID Numbers: Vortioxetine-1001
U1111-1208-2715 ( Other Identifier: WHO )
JapicCTI-183863 ( Registry Identifier: JapicCTI )
First Posted: February 19, 2018    Key Record Dates
Results First Posted: June 26, 2019
Last Update Posted: June 27, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Vortioxetine
Antidepressive Agents
Psychotropic Drugs
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists
Serotonin 5-HT3 Receptor Antagonists
Serotonin Antagonists